Literature DB >> 24899136

Imaging Characteristics in ALK Fusion-Positive Lung Adenocarcinomas by Using HRCT.

Takeo Nakada1, Sakae Okumura, Hiroaki Kuroda, Hirofumi Uehara, Mingyon Mun, Kengo Takeuchi, Ken Nakagawa.   

Abstract

OBJECTIVES: We aimed to identify high-resolution computed tomography (HRCT) features useful to distinguish the anaplastic lymphoma kinase gene (ALK) fusion-positive and negative lung adenocarcinomas.
METHODS: We included 236 surgically resected adenocarcinoma lesions, which included 27 consecutive ALK fusion-positive (AP) lesions, 115 epidermal growth factor receptor mutation-positive lesions, and 94 double-negative lesions. HRCT parameters including size, air bronchograms, pleural indentation, spiculation, and tumor disappearance rate (TDR) were compared. In addition, prevalence of small lesions (≤20 mm) and solid lesions (TDR ≤20%) were compared.
RESULTS: AP lesions were significantly smaller and had lower TDR (%) than ALK fusion-negative (AN) lesions (tumor diameter: 20.7 mm ± 14.1 mm vs. 27.4 mm ± 13.8 mm, respectively, p <0.01; TDR: 22.8% ± 24.8% vs. 44.8% ± 33.2%, respectively, p <0.01). All AP lesions >20 mm (n = 7, 25.9%) showed a solid pattern. Among all small lesions, AP lesions had lower TDR and more frequent spiculation than AN lesions (p <0.01). Among solid lesions, AP lesions were smaller than AN lesions (p = 0.01).
CONCLUSION: AP lung lesions were significantly smaller and had a lower TDR than AN lesions. Spiculation was more frequent in small lesions. Non-solid >20 mm lesions may be ALK fusion-negative.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24899136      PMCID: PMC4990087          DOI: 10.5761/atcs.oa.14-00093

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  16 in total

1.  EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Yuichi Sakairi; Takahiro Nakajima; Kazuhiro Yasufuku; Dai Ikebe; Hajime Kageyama; Manabu Soda; Kengo Takeuchi; Makiko Itami; Toshihiko Iizasa; Ichiro Yoshino; Hiroyuki Mano; Hideki Kimura
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Authors:  Akihiko Yoshida; Koji Tsuta; Harumi Nakamura; Takashi Kohno; Fumiaki Takahashi; Hisao Asamura; Ikuo Sekine; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Hitoshi Tsuda
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

3.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 4.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Authors:  Pasi A Jänne; Jeffrey A Engelman; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

5.  Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study.

Authors:  Morihito Okada; Teruaki Koike; Masahiko Higashiyama; Yasushi Yamato; Ken Kodama; Noriaki Tsubota
Journal:  J Thorac Cardiovasc Surg       Date:  2006-10       Impact factor: 5.209

6.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

Authors:  Masaki Tokumo; Shinichi Toyooka; Katsuyuki Kiura; Hisayuki Shigematsu; Kunitoshi Tomii; Motoi Aoe; Kouichi Ichimura; Toshihide Tsuda; Masaaki Yano; Kazunori Tsukuda; Masahiro Tabata; Hiroshi Ueoka; Mitsune Tanimoto; Hiroshi Date; Adi F Gazdar; Nobuyoshi Shimizu
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Satoko Hatano; Hironori Ninomiya; Noriko Motoi; Ming-yon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Mod Pathol       Date:  2009-02-20       Impact factor: 7.842

8.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Authors:  Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

9.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.

Authors:  K Sugio; H Uramoto; K Ono; T Oyama; T Hanagiri; M Sugaya; Y Ichiki; T So; S Nakata; M Morita; K Yasumoto
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  10 in total

1.  CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Soon Ho Yoon; Darragh F Halpenny; Sangwon Han; Chong Hyun Suh
Journal:  AJR Am J Roentgenol       Date:  2019-08-15       Impact factor: 3.959

2.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Authors:  Stefania Rizzo; Francesco Petrella; Valentina Buscarino; Federica De Maria; Sara Raimondi; Massimo Barberis; Caterina Fumagalli; Gianluca Spitaleri; Cristiano Rampinelli; Filippo De Marinis; Lorenzo Spaggiari; Massimo Bellomi
Journal:  Eur Radiol       Date:  2015-05-09       Impact factor: 5.315

3.  Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma.

Authors:  Yeonseok Choi; Ki-Hwan Kim; Byeong-Ho Jeong; Kyung-Jong Lee; Hojoong Kim; O Jung Kwon; Jhingook Kim; Yoon-La Choi; Ho Yun Lee; Sang-Won Um
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

4.  A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.

Authors:  Y Cao; H Xu
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

5.  Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Authors:  Yingying Miao; Suhua Zhu; Huijuan Li; Jiawei Zou; Qingqing Zhu; Tangfeng Lv; Yong Song
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients.

Authors:  Hiroaki Kuroda; Yusuke Sugita; Yuko Ohya; Tatsuya Yoshida; Takaaki Arimura; Noriaki Sakakura; Toyoaki Hida; Yasushi Yatabe; Yukinori Sakao
Journal:  Cancer Manag Res       Date:  2018-12-20       Impact factor: 3.989

7.  Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Yiyuan Cao; Haibo Xu; Meiyan Liao; Yanjuan Qu; Liying Xu; Dongyong Zhu; Bicheng Wang; Sufang Tian
Journal:  Int J Clin Oncol       Date:  2017-10-07       Impact factor: 3.402

8.  Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement.

Authors:  Katsutoshi Seto; Hiroaki Kuroda; Tatsuya Yoshida; Shozo Sakata; Tetsuya Mizuno; Noriaki Sakakura; Toyoaki Hida; Yasushi Yatabe; Yukinori Sakao
Journal:  Cancer Manag Res       Date:  2018-07-18       Impact factor: 3.989

9.  Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients.

Authors:  Lan Song; Zhenchen Zhu; Li Mao; Xiuli Li; Wei Han; Huayang Du; Huanwen Wu; Wei Song; Zhengyu Jin
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

10.  Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Authors:  Subba R Digumarthy; Dexter P Mendoza; Eric W Zhang; Jochen K Lennerz; Rebecca S Heist
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.